Table 2.

Published studies of ovarian suppression with gonadotropin-releasing hormone agonists

Reference	Year	Patients (n)	Chemotherapy regimen	Pregnancies (%)	Births (%)	Menses 1 year after therapy (%)	Menses at the end of follow-up (%)	Study type	Outcome
Fox and colleagues [27]	2003	24	AC, AC-T, FAC, AT-CMF	21	8	96	75	Prospective, single-arm	Ovarian function preservation
Del Mastro and colleagues [28]	2006	29	100% FEC	-	-	94	92	Prospective, single-arm	Ovarian function preservation
Recchia and colleagues [29]	2002	100	26% CMF, 11% FEC, 54% CMF + epirubicin, 9% HCST	3	2	100		Retrospective, single-arm	Ovarian function preservation
Urruticoechea and colleagues [30]	2007	50	78% FEC, 14% AC, 8% AC-T/D	16	16	86	90	Prospective, single-arm	Ovarian function preservation
Total		203

AC, adriamycin (doxorubicin), and cyclophosphamide; AC-T, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel); AC-T/D, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel)/docetaxel; AT-CMF, adriamycin (doxorubicin), taxol (paclitaxel), cyclophosphamide, methotrexate, and 5-fluorouracil; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; FAC, 5-fluorouracil, adriamycin (doxorubicin), and cyclophosphamide; FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; HCST, high dose chemotherapy and autologous peripheral blood progenitor cell transplantation.